<< Mandatory folic acid fortification may be unnecessary | Protein Huwe1 may be an important factor in the development of brain cancer >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

Scientific studies enough to warrant action on bisphenol A

Published on August 17, 2009 at 7:36 PM · No Comments

Scientists, physicians, consumers and environmental health advocates today responded to an FDA staff presentation on progress of their review of bisphenol A (BPA), a synthetic sex hormone linked to cancer, diabetes, heart problems and other illness. Congressmen Henry Waxman and Bart Stupak asked for FDA to review their evaluation of BPA.

Jen Sass, Ph.D., Natural Resources Defense Council, attended today's FDA meeting. "While the final report is not due until November 30th, we are glad that they will be including biomonitoring studies and other health studies ignored in previous evaluations of BPA. Representatives from manufacturers who use BPA certainly turned out in force today." Accusations of industry influence on FDA decision making on BPA plagued the agency last year.

Janet Nudelman of the Breast Cancer Fund said, "The science on BPA is extensive and deeply troubling. We're encouraged that the FDA is re-assessing the safety of this toxic chemical, and we urge them to take into account all of the credible, peer-reviewed research on low-dose exposures."

Dr. Sarah Janssen, with Natural Resources Defense Council, said "Under new leadership, FDA has the opportunity to demonstrate that their evaluations can be based on the full scope of scientific evidence. The weight of evidence suggests that BPA is not safe in our food supply and exposure puts the public, especially children, at risk."

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading